| Objective To investigate the predictive value and the interactions of serum interleukin-13（IL-13） and matrix metalloproteinase-9（MMP-9） in acute exacerbation of bronchiectasis（BE）. Methods A total of 150 patients with BE admitted to Department of Respiratory and Critical Care Medicine, Hebei Provincial Chest Hospital from May 2020 to December 2022 were selected and divided into divided into occurrence and non-occurrence groups based on whether acute exacerbation occurred within one year. The clinical data, serum levels of IL-13 and MMP-9 were compared, and the relationship between serum indicators and acute exacerbation of BE was analyzed. The value and interaction of serum indicators in jointly predicting acute exacerbation of BE were also analyzed. Results Patients with acute exacerbation had a lower forced expiratory volume in one second to predicted value percentage（FEV1%pred） than those without acute exacerbation, and significantly higher levels of partial pressure of carbon dioxide（PaCO2）, Functional Assessment of Chronic Bronchiectasis Evaluation（FACED） score, serum IL-13, and MMP-9（P<0.05）. FEV1%pred, PaCO2, FACED score, serum IL-13, and MMP-9 levels were all influencing factors for acute exacerbation of BE（P<0.05）. High levels of IL-13 and MMP-9 simultaneous exposure to acute exacerbation of BE significantly increased the risk. Conventional scheme: The AUC of FEV1%pred, PaCO2, and FACED score combined in predicting acute exacerbation of BE was 0.850. New scheme: The AUC of serum IL-13 and MMP-9 combined with the conventional scheme in predicting acute exacerbation of BE was 0.933, which was significantly higher than the conventional scheme. Conclusion The combination of serum IL-13 and MMP-9 in patients with acute exacerbation of BE can help improve the predictive value of acute exacerbation of BE, and their simultaneous exposure can synergistically promote the risk of acute exacerbation. |
